Bleeding Risk and Thrombotic Events in Cardiac Amyloidosis: A Critical Assessment

Abstract Cardiac amyloidosis (CA) is a condition in which amyloid fibres are deposited in the cardiac muscle tissue, causing tachyarrhythmias, heart failure, or sudden cardiac death. We report a case of immunoglobulin light chain cardiac amyloidosis in which the patient experienced neurological symptoms multiple times during the course of the disease, with magnetic resonance imaging showed cerebral infarction and cerebral haemorrhage. Ischemic and haemorrhagic stroke are complications in CA patients, among which ischemic stroke may be closely associated with poor prognosis and increased all-cause mortality, in diagnosed patient systematic assessment and monitoring of bleeding risk and thrombotic events should be strengthened. When CA is combined with atrial fibrillation (AF), atrial or ventricular wall thrombosis, and cardiogenic cerebral embolism, antithrombotic therapy under comprehensive bleeding risk assessment is necessary. If AF and atrial or ventricular wall thrombosis are not detected, and ischemic and haemorrhagicstroke coexist, it is important to consider how to choose anticoagulant treatment.